A/61/338 24 42 CESCR, general comment 14, paras. 12 (1) and 43 (4). 43 CESCR, general comment 14, paras. 34-37. 44 For example, see the Special Rapporteur’s reports on the World Trade Organization (E/CN.4/2004/49/Add.1, from para. 66), and Peru (E/CN.4/2005/51/Add.3, from para. 47). 45 WHO Medicines Strategy, 2004-2007, chapter 4. 46 Global Corruption Report, Transparency International, 2006. 47 Hogerzeil, H., “Essential medicines and human rights”, WHO Bulletin, 2006. 48 The World Medicines Situation, WHO, 2004. 49 Increasing people’s access to essential medicines in developing countries, DFID, 2005. 50 Some of this information has been provided while on mission and confirmed in, for example, Interim Report of Task Force 5 Working Group on Access to Essential Medicines, Millennium Project, 2004, and Cullet, P., “Patents and medicines: the relationship between TRIPS and the human right to health”, International Affairs, 2003. 51 On the latter, see Moran, M. and others, “The new landscape of neglected disease drug development”, The Welcome Trust, 2005. 52 The right to health: a duty for whom?: International symposium report, Novartis Foundation for Sustainable Development, 2004. 53 See “A guide for integrating human rights into business management” available at http://www.blihr.org/. 54 E.g. Public Health, Innovation and Intellectual Property Rights, CIPIH, 2006; Increasing people’s access to essential medicines in developing countries, DFID, 2005; Leisinger, K., “On Corporate Responsibility and Human Rights”, 2006; Branding the Cure, Consumers International, 2006. 55 The draft is available at http://www2.essex.ac.uk/human_rights_centre/rth/rapporteur.shtm and comments may be sent to rthu@essex.ac.uk. 56 Robinson, M., “The business case for human rights” in Visions of Ethical Business, Financial Times Management (London, Financial Times Professional, 1998); de Mello, S.V., “Human rights: what role for business?” 2(1) New Academy Review (2003). 57 For more information on Global Compact, see http://www.unglobalcompact.org/. 58 The OECD Guidelines for Multinational Enterprises, 2000. 59 Norms on the responsibilities of transnational corporations and other business enterprises with regard to human rights (E/CN.4/Sub.2/2003/12/Rev.2) (2003). 60 AIDS Access Foundation and others v. Bristol-Myers Squibb and others, 2002 (10) BC Tor Por 34/2544. 61 “Novartis Corporate Citizenship Guideline 4 (Human Rights)”, available at www.novartisfoundation.com. 62 A view consistent with the interim report of the Special Representative of the Secretary-General on the issue of human rights and transnational corporations, see, for example, E/CN.4/2006/97, para. 61, last sentence. Generally, see Clapham, A., Human Rights Obligations of Non-State Actors, 2006. 63 CESCR, general comment 14. 06-51997